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Objective: Information about treatment side effects can increase their occur-
rence; breast cancer (BC) patients showed increased cognitive problem report-
ing (CPR) and decreased memory performance after information about
cognitive side effects. The current study extends previous research on adverse
information effects (AIE) by investigating (a) risk factors, (b) underlying
mechanisms and (c) an intervention to reduce AIE.
Design: In an online experiment, 175 female BC patients were randomly
assigned to one of three conditions. In the two experimental groups, patients
were informed about the possible occurrence of cognitive problems after
chemotherapy with (intervention group) or without (experimental group) reas-
suring information that ‘there are still patients who score well on memory
tests’. In the control group, no reference to chemotherapy-related cognitive
problems was made.
Main outcome measures: Main dependent measure was CPR. Four moderat-
ing and ﬁve mediating processes were examined.
Results: CPR increased with higher levels of stigma consciousness in the two
experimental groups, but not in the no-information control group.
Conclusion: Merely informing patients about cognitive side effects may
increase their occurrence, especially among individuals vulnerable to patient
stereotypes. Adding reassuring information is not sufﬁcient to reduce AIE.
Keywords: cognitive problems; nocebo; breast cancer; stereotype threat;
information
A substantial group of women treated for breast cancer (BC; 17–75%) have cognitive
problems after chemotherapy, sometimes persisting well into the survivorship period
(up to 20 years after therapy). Core impairments of this ‘chemobrain’ phenomenon
include memory problems, slowing of information processing speed and executive dys-
function, impacting quality of life and daily functioning (Ahles, Root, & Ryan, 2012;
Wefel & Schagen, 2012). So far, research has focused mostly on biological factors as
explanatory mechanisms (for a review, see Janelsins, Kesler, Ahles, & Morrow, 2014;
Wefel & Schagen, 2012), but two recent studies suggest that (mere) information may
also contribute to the occurrence of cognitive side effects.
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Speciﬁcally, communicating that ‘chemotherapy may be associated with cognitive
difﬁculties’ before completing questionnaires and a neuropsychological test increased
the reporting of cognitive problems (CPR) and decreased cognitive performance on a
verbal memory task for BC patients (Schagen, Das, & van Dam, 2009; Schagen, Das,
& Vermeulen, 2012). The processes that drive these effects are still unclear.
The present research introduces the label adverse information effects (AIE) to refer to
negative effects of medical information about treatment. Building on nocebo and stereo-
type threat literature, we extend previous ﬁndings in three speciﬁc ways, by investigating
(a) risk factors; (b) underlying mechanisms; and (c) an intervention to reduce AIE.
What triggers AIE? Explanations from nocebo and stereotype threat research
AIE have thus far been established on cognitive problem reporting (CPR) and neu-
ropsychological test scores. In a ﬁrst study (Schagen et al., 2009), information about
cognitive side effects of chemotherapy increased CPR, but only for BC patients without
a history of chemotherapy. This effect was independent of age, education level and neg-
ative affect. A second study (Schagen et al., 2012) reported that cancer patients treated
with chemotherapy had higher levels of CPR and recalled fewer words on a word-learn-
ing test after being informed about the link between chemotherapy and cognition than
without such information. AIE ﬁndings correspond with studies in the area of mild head
injury (MHI) (e.g. Ozen & Fernandes, 2011; Suhr & Gunstad, 2002) that showed
increased CPR and diminished performance on neuropsychological tests, when individu-
als diagnosed with MHI have their attention called to prior head injury. Comparable
effects were found for older individuals who were reminded of the expectation that
‘memory performance declines with age’ prior to the neuropsychological tests and self-
report measures (Lamont, Swift, & Abrams, 2015).
Little is known about the mechanisms that are at play in AIE, but we propose that the-
oretical explanations from both nocebo and stereotype threat research could be relevant.
The nocebo effect occurs for an inert or active treatment or medication when the expecta-
tion of negative symptoms results in increased experience of these symptoms (Faasse &
Petrie, 2013). For example, individuals may report more pain after verbal suggestions for
pain increase (Petersen et al., 2014). Nocebo literature has suggested that expectations,
associative learning and suggestion may trigger the nocebo effect. Most studies in this
domain have focused on biochemical factors and brain processes involved following neg-
ative expectations about for example, pain (e.g. Koyama, McHafﬁe, Laurienti, & Coghill,
2005). Research on the role of suggestion has mostly explicitly varied probability or
severity estimates, but not examined effects of merely adapting or reframing patient infor-
mation without adding beneﬁcial information about the treatment.
A research domain that appears especially promising to further explore the role of
information in aversive responses following treatment is the stereotype threat literature.
Stereotype threat is implied when performance, for example, on a math test, is impaired
after individuals are provided with stereotypical information about their group prior to
the test (Steele, 1997; Steele & Aronson, 1995). These effects are proposed to occur
because the threat of being judged or negatively stereotyped may interfere with perfor-
mance in several ways, for instance, by decreasing motivation or increasing negative
emotions (Kit, Tuokko, & Mateer, 2008). Stereotype threat has been researched
extensively in the area of racial and gender stereotypes; we propose it may also apply
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to AIE. Speciﬁcally, activation of a stereotype or schema about a category – such as
‘cancer patients have chemobrain’ – may unconsciously lead to behaviour in correspon-
dence with that stereotype for individuals who are part of the group under threat.
The present research tests whether stereotype threat assumptions also apply to AIE.
Research from different ﬁelds shows that stereotypes can play a role in the medical
domain in general and in cancer patients in particular. Individuals diagnosed with can-
cer may experience stereotypical expectancies or some levels of (social) stigma, i.e.
‘the speciﬁc sense of being different from others as a consequence of being assigned to
the patient role’ (Koller et al., 1996, p. 988). In the present research, we examine the
role of implicit association activation in the occurrence of AIE using a Word Comple-
tion Task. Speciﬁcally, we examine whether reading information about cognitive prob-
lems after chemotherapy treatment activates: (a) implicit stereotypical associations with
cognitive problems, e.g. being ‘dumb’ or ‘demented’, and whether (b) information
about cognitive problems after chemotherapy activates or deactivates implicit associa-
tions related to the patient category (RQ1).
Related to the ﬁrst goal of the present study, several other relevant underlying pro-
cesses of AIE were examined. An extensive body of literature on stereotype threat out-
side the clinical setting suggests that stereotype threat effects operate through various
cognitive, emotional and motivational mechanisms (for an overview, see Kit et al.,
2008 and Schmader & Beilock, 2011). Although these studies have not revealed conclu-
sive evidence regarding underlying processes, they have shown that reduced feelings of
self-efﬁcacy (Kit, Mateer, Tuokko, & Spencer-Rodgers, 2014; Spencer, Steele, &
Quinn, 1999), increased worry about performance (Steele, Spencer, & Aronson, 2002),
increased (Jamieson & Harkins, 2007; Smith, 2004) or decreased (Kit et al., 2008;
Smith, 2004) motivation and effort can play a role in stereotype threat effects. Building
on these ﬁndings, we examined whether information about cognitive side effects
increases or decreases patients’ motivation levels (Jamieson & Harkins, 2007; Kit et al.,
2008), affected patients’ worry about their performance (Steele et al., 2002) and affected
their feelings of self-efﬁcacy (Spencer et al., 1999), and whether these factors also
predicted CPR (RQ2).
Risk factors of AIE: who is most vulnerable?
A second goal of this study was to examine risk factors for AIE. Although one would
expect that individuals for whom the information is not personally relevant (not treated
with chemotherapy) should not be vulnerable for information about cognitive decline
after chemotherapy, previous studies among patients with and without chemotherapy
showed mixed ﬁndings regarding which patients are most at risk (Schagen et al., 2009,
2012). The present research aims to examine whether these divergent ﬁndings may be
reconciled by including risk factors for stereotype threat that have been identiﬁed in
research on racial and gender stereotypes (see for a review Kit et al., 2008). First,
stigma consciousness – i.e. ‘the extent to which individuals are chronically self-con-
scious of their stigmatized status’ (Brown & Pinel, 2003, p. 627) will be examined as a
risk factor. Research has shown that individuals differ in their vulnerability to race or
gender stereotypes depending on their perception of how much they are stereotyped by
others and how much they are affected by it. Especially individuals high in stigma con-
sciousness may be negatively affected by stereotype threat (Brown & Pinel, 2003).
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Second, research shows stronger stereotype threat effects when the domain or group
under threat is personally relevant (Aronson et al., 1999). Translated to AIE, an individ-
ual high in domain identiﬁcation, (i.e. how greatly patients value their cognitive perfor-
mance) may be more likely to be negatively affected by threatening information
regarding their performance than an individual low in domain identiﬁcation. Likewise,
individuals who highly identify with the group under threat and who consider category
membership to be an important part of their identity (i.e. to what extent an individual
identiﬁes with other cancer patients) may be more affected when their group status is
threatened than low identiﬁers (Spears, Doosje, & Ellemers, 1997; Steele et al., 2002).
The present study includes both patients with and without chemotherapy experience
and additionally assessed individual differences in identiﬁcation with the patient cate-
gory, identiﬁcation with the cognition domain and stigma consciousness, with the goal
to explore if previous divergent ﬁndings regarding the role of previous experience with
chemotherapy can perhaps be explained by a third variable, speciﬁcally varying levels
of stigma consciousness, domain or group identiﬁcation (RQ3).
Reducing AIE: intervention possibilities
A third goal of the present study was to provide a ﬁrst test of an informational intervention
aimed at reducing AIE among cancer patients. Nocebo and placebo research point to the
importance of enhancing positive expectancies in order to decrease nocebo effects, but
experimental studies that speciﬁcally examine effects of adapting or reframing patient
information are scarce. There are some examples of studies that focused on enhancing pla-
cebo or preventing nocebo by varying patient information or by suggestion, but these stud-
ies mostly manipulated probability or severity estimates or provided additional beneﬁt
information about the treatment (e.g. Heisig, Shedden-Mora, Hidalgo, & Nestoriuc, 2015).
Research outside the clinical domain has found several ways to diminish stereotype
threat effects, for example, by forewarning (Johns, Schmader, & Martens, 2005), by
allowing individuals to afﬁrm a valued personal characteristic – in accordance with
self-afﬁrmation theory (Steele, 1988) – or by providing them with a positive identity
(McGlone & Aronson, 2007; Sherman et al., 2013).
Finally, research on doctor–patient communication suggests that patients’ expectations
about treatment can be altered by providing positive information about the treatment – for
example, stating ‘that a therapy is ‘good’, ‘safe’ or ‘effective’, and giving support or reas-
surance’ – can positively inﬂuence health outcomes (Di Blassi, Harkness, Ernst, Georgiou,
& Kleijnen, 2001, p. 758; Verheul, Sanders, & Bensing, 2010). Because the latter ﬁndings
directly pertain to the medical context and could be effectively implemented in a short
information letter about the relationship between chemotherapy and cognitive complaints,
the current study examined whether adding reassuring and positive information to the
threatening medical information would diminish AIE (RQ4).
Method
Design and participants
Patients were recruited online, by posting a link on 15 Dutch forums and websites, both
related and unrelated to (breast) cancer (May–June 2011). With approval of the website
owners or moderators, a recruitment text with a request to participate in an online
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questionnaire about ‘complaints and symptoms that can be experienced by cancer patients
after diagnosis and treatment’ was posted together with the survey link. Because no names
or other identifying information was requested, no signed consent form was required. A
total of 236 cancer patients1 responded by ﬁlling out the questionnaire and were randomly
assigned to one of three groups (experimental, intervention or control) in the online exper-
iment. After opening the survey link, the following general introduction text was pre-
sented to all participants (in Dutch): ‘Dear reader, Welcome to this survey. When you
click on “next” the questionnaire will start. This questionnaire is about complaints and
symptoms that cancer patients can experience after different treatments. We would like to
ask you to carefully complete this survey. There is no time limit, you can take as much
time as you like. Please complete the questionnaire in one go. Completing the question-
naire will take about 25 min. Your data will be treated conﬁdentially and anonymously.
Thank you for your cooperation’. Although this introduction text and the recruitment text
accompanying the survey link were directed at individuals with a cancer diagnosis in gen-
eral, and did not differentiate between individuals with and without chemotherapy experi-
ence, the vast majority of the respondents were women who had been treated in the past
for BC (n = 202 of 236 participants). Due to this imbalance, we decided to create a homo-
geneous sample, by excluding the small number of patients with other diagnoses (n = 15)
and males (n = 7), as well as patients who at the time of the assessment received
chemotherapy (n = 14). Also, as ‘CPR’ was the main outcome measure in this study, the
analysis were done for those who completed the questions regarding this main dependent
variable (n = 175). The cases that were excluded from the analysis (n = 25) were equally
distributed among the three conditions, χ2(2, N = 200) = .40, p = .82. From the original
sample of 236 participants, a total of 61 cases were thus excluded from analysis.
Of the ﬁnal sample of 175 BC patients, 76% were treated with and 24% did not
undergo chemotherapy. The three groups of the ﬁnal sample were equally distributed
with regard to all relevant demographic and clinical variables (Table 1).
Procedure and materials
Participants were randomly assigned to one of three conditions by computer. The ﬁrst
experimental group (n = 56) received the following introduction (in Dutch): ‘Before you
start, please carefully read the information below. For many cancer patients, chemotherapy
is an important part of their treatment. We know from experience that some patients
receiving chemotherapy experience complaints regarding their memory ability and their
ability to concentrate. The goal of this study is to gain more insight in this relationship.
This study is important to reveal how such complaints could be prevented in future. In this
study you will be, among others, asked whether or not you experience cognitive com-
plaints. In addition, there is a short test that measures cognitive performance’ (experimen-
tal group) (Schagen et al., 2009, 2012). The second experimental group (intervention
group) received the same information plus two positive and reassuring sentences: ‘Before
you start, please carefully read the information below. For many cancer patients,
chemotherapy is an important part of their treatment. We know from experience that some
patients receiving chemotherapy experience complaints regarding their memory ability
and their ability to concentrate. However, there are also many patients who do not experi-
ence these complaints. In this study you will be, among others, asked whether or not you
experience cognitive complaints. In addition, there is a short test that measures cognitive
82 W. Jacobs et al.
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performance. We know that patients with memory- and concentration problems often still
perform well on this test’ (n = 59) (Di Blassi et al., 2001; Johns et al., 2005). The control
group received a one-sentence neutral introduction without any reference to chemotherapy
or cognitive difﬁculties: ‘Thank you for your cooperation’ (n = 60) (Schagen et al., 2009,
2012). This procedure resembles common medical practice, in which patients are some-
times informed about the possibility of cognitive side effects, and other times are not
informed about this possibility.
After reading the experimental text, all groups completed an online questionnaire.
The dependent variable of interest was CPR. The questionnaire measuring CPR was
derived from earlier research in this domain (Schagen et al., 2009, 2012). This survey
was part of a more extensive project on short- and long-term effects of being informed
about the cognitive side effects of cancer treatment on CPR and cognitive performance.
Measures
Dependent measures
CPR was measured with 10 ﬁve-point Likert scale items (very often–never) of the
subscales ‘absent-mindedness’ and ‘names and words’ of the Cognitive Failure
Table 1. Demographic and clinical variables.
Group
Experimental Intervention Control P (F or χ2)
n = 56 n = 59 n = 60
Age mean (SD) 49.55 (8.39) 50.58 (8.85) 48.02 (9.34) .29
Chemotherapy % (n/N) 80.4% (45) 71.2% (42) 76.7% (46) .51
Endocrine treatment % (n/N) 62.5% (35) 55.9% (33) 66.7% (40) .48
Currently 46.4% (26) 39.0% (23) 56.7% (34) .15
Past 53.6% (30) 42.4% (25) 56.7% (34) .26
Radiotherapy % (n/N) 66.1% (37) 69.5% (41) 65.0% (39) .86
Currently 5.4% (3) 1.7% (1) .0% (0) .15
Past 60.7% (34) 67.8% (40) 65.0% (39) .73
Time since diagnosis, yrs (SD) 3.49 (2.68) 4.00 (3.59) 4.00 (3.59) .57
BC diagnosis +/− other % (n/N) 98.2% (55) 93.2% (55) 93.3% (56) .39
Breast 98.2% (55) 93.2% (55) 93.3% (56) .82
Breast and lung .0% (0) 1.7% (1) .0% (0)
Breast and skin .0% (0) 1.7% (1) 1.7% (1)
Breast and gynaecological 1.8% (1) 1.7% (1) 3.3% (2)
Breast and else .0% (0) 1.7% (1) 1.7% (1)
Employed % (n/N) .46
Yes 57.1% (32) 61.0% (36) 53.3% (32)
No 30.4% (17) 32.2% (19) 28.3% (17)
Temporarily not 12.5% (7) 6.8% (4) 18.3% (11)
Education level% (n/N) .94
Low 21.8% (12) 22.4% (13) 22.0% (13)
Medium 32.7% (18) 39.7% (23) 37.3% (22)
High 45.5% (25) 37.9% (22) 40.7% (24)
Pre-existing knowledge % (n/N) .88
No 6.4% (3) 8.5% (4) 7.5% (4)
Some 23.4% (11) 31.9% (15) 26.4% (14)
Yes 70.2% (33) 59.6% (28) 66.0% (35)
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Questionnaire (Broadbent, Cooper, FitzGerald, & Parkes, 1982; Ponds, Roozendaal, &
Jolles, 2004; Schagen et al., 2012; α = .89). This scale is a standard questionnaire to
assess CPR. Participants indicated how often (in general) they experienced memory
problems, e.g. ‘How often do you ﬁnd you forget appointments?’.
Implicit cognition stereotype and patient category activation was measured by
asking patients to complete 28 word fragments of which four fragments could be com-
pleted relating to a ‘cognition stereotype’ and 8 to a ‘patient category’, e.g. _ANCER
can be completed as CANCER or DANCER. The other words were neutral words, e.g.
SH(EE)P or SH(AR)P (Das, Bushman, Bezemer, Kerkhof, & Vermeulen, 2009). The
number of word fragments completed relating to cognition or to being a patient were
summed separately to two sum scores. Higher scores denote higher levels of stereotype
activation. All words were pretested before use in this study (n = 33).
Motivation level was measured by two ﬁve-point Likert scale items (strongly
disagree–strongly agree) (Seibt & Förster, 2004; r = .73, p = .00) assessing whether
participants are motivated to perform well on a memory task. For example, ‘I am
motivated to do well on a memory task’.
To measure self-efﬁcacy, participants rated on four ﬁve-point Likert scale items
(strongly disagree–strongly agree) derived from the translated self-efﬁcacy scale, their
ability to do well on a memory test (Spencer et al., 1999; α = .82). For instance, ‘I
think I have the cognitive ability to perform well on a memory test’.
Self-reported worry about performance was measured by three ﬁve-point Likert scale
items (strongly disagree–strongly agree), assessing level of worries when thinking of a
memory task (α = .79), e.g. ‘I am worried about my performance on a memory task’.
Moderators
Stigma consciousness was assessed by eight ﬁve-point Likert scale items (strongly dis-
agree–strongly agree) derived from the Stigma Consciousness Questionnaire (Brown &
Pinel, 2003; α = .83). Items were translated to Dutch and adapted for use in a cancer
population. Participants indicated ‘the extent to which they expect to be stereotyped by
others’ (Pinel, 1999, p. 114) and are personally inﬂuenced by these (cancer) patient
stereotypes, e.g. ‘Most other people have a lot more negative thoughts about cancer
patients than they actually express’.
Domain identiﬁcation was assessed with six ﬁve-point Likert scale items (strongly
disagree–strongly agree) derived from the Mathematics Identiﬁcation Questionnaire
(Brown & Josephs, 2000) and the Domain Identiﬁcation Questionnaire (Smith & White,
2001; α = .84). These items assessed the extent to which participants identify with the
domain of ‘cognition’ and the level of importance of their thinking ability to their self-
identity, e.g. ‘My cognition (thinking ability) is important to me’.
Group identiﬁcation to the category ‘cancer patient’ was measured by three
ﬁve-point Likert scale items (strongly disagree–strongly agree) derived from Doosje,
Ellemers and Spears (1995) and Spears et al. (1997), and three ﬁve-point scale items of
the collective self-esteem scale (Luhtanen & Crocker, 1992; α = .65). These items were
adapted to examine the perceived importance of patient identity to self-image
(Schmader, 2002), e.g. ‘Being a cancer patient is an important part of my self-image’.
Chemotherapy experience was measured by asking participants to indicate whether
they currently or in the past underwent chemotherapy or not (no/yes).
84 W. Jacobs et al.
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Covariates
Pre-existing knowledge about chemotherapy-induced cognitive problems (prior to the
experiment) was measured by two ﬁve-point Likert scale items (not at all–totally)
(r = .46, p < .001); e.g. ‘To what extent are you familiar with the fact that some patients
experience memory and concentration problems after cancer treatment’.
Affect was measured by six ﬁve-point Likert scale items (strongly disagree–strongly
agree) taken from the Positive and Negative Affect Schedule PANAS (Watson, Clark,
& Tellegen, 1988; α = .82). Participants indicated the extent to which they experienced
a speciﬁc emotion at that moment (e.g. irritable); higher scores indicate more positive
affect (Schagen et al., 2009).
Other cancer-related symptoms were measured by four ﬁve-point Likert scale items
(very often–never) derived from the Depression and Anxiety questionnaire (De Jonghe,
Huyser, Swinkels, Sno, & Schalken, 1990; α = .71), concerning the frequency of experi-
encing pain, fatigue, decreased endurance and sleeping problems. These questions were
previously used in studies on the cognitive side effects of chemotherapy (e.g. Schagen
et al., 1999, 2009). Higher scores indicate a higher frequency of symptoms during the
previous weeks.
Statistical analyses
Data were analysed with SPSS Version 20.0 (SPSS, Inc, IL, USA) using one and two
way analyses of (co)variance with group (experimental, intervention, control) and
chemotherapy experience (yes, no) as independent factors and stigma consciousness,
domain identiﬁcation and group identiﬁcation as continuous moderators (see Aiken &
West, 1991 for this speciﬁc analysis). Using this procedure, tests of differences between
respondents with different levels of the moderator can be performed without using a
median split. All observations are thus included in the analysis (e.g. Royston, Altman,
& Sauerbrei, 2006). Because no moderating effects were observed for chemotherapy
experience, domain and group identiﬁcation (all F’s ≤ 1.52), only the analyses with
stigma consciousness are reported below. See the online supplemental material for a
detailed overview of all results (p-values, means and standard deviations). Correlations
were examined; when potential confounds were signiﬁcantly related to the dependent
variable, these variables were included as covariates in the main analyses. Bootstrapping
procedures were used to test for mediation (Preacher & Hayes, 2008).
Levene’s tests were conducted for all dependent variables; ﬁndings are only reported
for signiﬁcant Levene’s test scores. Effect sizes were calculated with partial eta squared,
with effect sizes of .01–.06 considered as small, .06–.14 as medium and above .14 as
large (Cohen, 1988).
Results
Implicit stereotype and category activation
First, we examined whether reading information about cognitive problems after chemother-
apy activated: (a) implicit stereotypical associations with cognitive problems (e.g. being
‘dumb’ or ‘demented’) and whether (b) information about cognitive problems after
chemotherapy activated implicit associations related to the patient category (RQ1). There
was no signiﬁcant main effect of group or interaction effect, but the ANOVA on activation
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of the cognition stereotype with group (experimental, intervention, control) and stigma
consciousness (continuous) as predictor revealed a main effect of stigma consciousness,
F(5,141) = 6.26, p = .01, ηp
2 = .04. Individuals high in stigma consciousness had higher
levels of associations with cognitive problems, t(1, 145) = 2.42, p = .017, b(SEb) = .27 (.11),
β = .20.
A similar ANOVA on activation of the patient category words showed no main
effect of group or interaction effect, but again revealed a main effect of stigma con-
sciousness in the opposite direction, F(5,141) = 6.68, p = .01, g2p = .05. Individuals low
in stigma consciousness showed higher levels of patient category activation, t(1, 145)
= −2.44, p = .016, b(SEb) = −.42 (.17), β = −.20.
Cognitive problem reporting
Further, we examined whether reading information about cognitive problems after
chemotherapy treatment inﬂuenced CPR. Also, stigma consciousness was examined as
risk factor (RQ3) and it was investigated whether adding reassuring and positive infor-
mation to the threatening medical information could diminish the AIE (RQ4). The
ANOVA on CPR with group (experimental, intervention, control) and stigma conscious-
ness (continuous) as predictors revealed no main effect of group (F(5,141) = .06,
p = .941, g2p = .00). There was, however, a signiﬁcant main effect of stigma conscious-
ness on CPR (F(5,141) = 23.67, p < .001, g2p = .14), indicating that individuals with
higher levels of stigma consciousness more frequently reported cognitive problems. In
addition, the interaction effect of group and stigma consciousness on CPR was signiﬁ-
cant (F(5,141) = 3.32, p = .039, g2p = .05). For individuals in the experimental and inter-
vention condition, the frequency of CPR increased with higher levels of stigma
consciousness, t(1,45) = 4.01, p < .001, b(SEb) = .57 (.14), β = .51 and t(1,45) = 3.60,
p = .001, b(SEb) = .53 (.15), β = .47. For patients in the control condition there was no
relationship between stigma consciousness and CPR, t(1,51) = .75, p = .45, b(SEb) =
.11 (.14), β = .11 (see Figure 1).
Figure 1. Interaction effect of experimental condition and stigma consciousness on CPR
controlling for affect and other cancer-related symptoms.
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Other risk factors were also examined. Similar ANOVAs with chemotherapy experi-
ence, domain and group identiﬁcation (RQ3) as moderators revealed no additional sig-
niﬁcant interaction effects (all F’s ≤ 1.52).
Worry, motivation and self-efﬁcacy
We examined whether information about cognitive side effects increases or decreases
patients’ motivation levels, affected patients’ worry about their performance and
affected their feelings of self-efﬁcacy, and whether these factors also predicted CPR
(RQ2). The ANOVA on worry with group (experimental, intervention, control) and
stigma consciousness (continuous) as predictors showed a marginally signiﬁcant effect
of experimental condition on worry (F(5,141) = 2.60, p = .078, g2p = .04). Individuals in
the experimental group showed marginally signiﬁcant higher levels of worry (M = 2.94,
SD = .80) than individuals in the control group (M = 2.58, SD = .83) (p = .07). The
levels of worry in the intervention condition (M = 2.84, SD = .78) and the other two
conditions were similar (p’s ≥ .32).
There was a main effect of stigma consciousness (F(5,141) = 6.90, p = .01,
g2p = .05): individuals with higher levels of stigma consciousness reported higher levels
of worry, t(1,145) = 2.57, p = .011, b(SEb) = .25 (.10), β = .21. No interaction was
found. The ANOVAs on motivation and self-efﬁcacy with group and stigma conscious-
ness as predictors showed no main or interaction effects (F’s ≤ 2.64).
Controlling for potential confounds
To verify the robustness of our main ﬁndings, we reran the ANOVAs of our main ﬁnd-
ings regarding CPR and stigma consciousness (RQ3 and RQ4), this time controlling for
potential confounds. Other cancer-related symptoms and affect were signiﬁcantly related
to CPR. Both variables were included as covariates in an ANCOVA on CPR. This anal-
ysis showed again no main effect of experimental group. The main effect for stigma
consciousness remained signiﬁcant (F(7,139) = 10.22, p = .002, g2p = .07), as did the
interaction effect of group and stigma consciousness on CPR (F(7,139) = 4.06, p = .02,
g2p = .06). The same pattern of ﬁndings was observed; for individuals in the experimen-
tal and intervention condition, the frequency of CPR increased with higher levels of
stigma consciousness, t(3,43) = 3.11, p = .003, b(SEb) = .50 (.16), β = .44 and t(3,43) =
2.49, p = .017, b(SEb) = .36 (.15), β = .32. For patients in the control condition there
was no relationship between stigma consciousness and CPR, t(3,49) = .24, p = .81, b
(SEb) = .03 (.14), β = .03 (see Figure 1).
Similar ANCOVAs with chemotherapy experience, domain and group identiﬁcation
(RQ3) as moderators showed again no additional signiﬁcant interaction effects (all
F’s ≤ 1.10). Finally, when covariates were included in the model, bootstrapping proce-
dures (Preacher & Hayes, 2008), showed no evidence for mediation by the proposed
mediators.
Discussion
Information about the association between cognitive difﬁculties and chemotherapy
increased CPR especially for individuals who consider themselves to be stereotyped as
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cancer patients by others. These ﬁndings extend previous research on AIE for BC
patients (Schagen et al., 2009, 2012) and show that concepts from social psychological
research, such as stereotype threat and stigma consciousness, may also be of importance
in the clinical domain.
Being highly aware of cancer patient stereotypes and of one’s own stigmatised sta-
tus (Brown & Pinel, 2003) may constitute a risk factor for negative effects of treatment
information. These ﬁndings correspond with stereotype threat research, which had sug-
gested that information is more likely to have negative effects among individuals who
consider the information as relevant to their self-concepts (e.g. Schmader, 2002). Our
ﬁndings suggest that the extent to which someone expects to be stereotyped as a cancer
patient by others is more important than other factors related to the relevance of a
stereotype, such as chemotherapy experience, group and domain identiﬁcation. In the
present research, these factors did not play a signiﬁcant role in the prediction of
cognitive complaints.
Although one would expect individuals with actual chemotherapy experience to be
affected only by information about the potential relationship between chemotherapy and
cognitive problems, previous research showed inconsistent ﬁndings (Schagen et al.,
2009, 2012). In the current study, BC patients with and without chemotherapy experi-
ence were equally affected by information about chemotherapy-associated cognitive
problems, which suggests that it is not the actual experience with chemotherapy that is
important in increasing AIE.
The signiﬁcant effect of stigma consciousness and the absence of interaction effects
of domain and group identiﬁcation may point to the importance of social effects of
diminished cognitive functioning and the fear of social consequences of being assigned
to the cancer patient role. What might play a role here is that the (self-) threatening
information in this study (cognitive decline after cancer) is not as visible as ‘being a
woman’, but is hidden (Quinn, 2006). Patients high in stigma consciousness may be
more afraid of disclosing a stigmatised identity to others than patients low in stigma
consciousness. One essential difference between domain and group identiﬁcation and
stigma consciousness is that stigma consciousness focuses on the judgement or view by
others and the extent to which an individual values being considered a cancer patient
by others, whereas domain or group identiﬁcation focuses on the importance of the
domain or group for the patients themselves. Hence, (worrying about) social or stigma-
tising factors may play a role in being at risk for AIE concerning cognitive problems
after a cancer diagnosis and treatment.
This corresponds with the ﬁndings of Koller et al. (1996) that experienced social
stigma was associated with negative affect and symptom reporting of cancer patients.
Individuals who consider themselves to be highly stigmatised as a cancer patient by
others may be more strongly affected by negative information about their group, and
more motivated to disprove the stereotype. This may also explain why the intervention
developed in this study was unsuccessful. The intervention was primarily directed at
reassurance and at increasing patients’ self-conﬁdence regarding cognitive performance.
Future studies should examine interventions directed at diminishing worries about the
social consequences of cognitive difﬁculties and cancer. The null-ﬁndings here may also
be explained by linguistic or negation bias, i.e. the idea that language reﬂects and
implicitly communicates stereotypical expectancies. Both texts may have created the
expectation of ‘problems’ (Burgers, Beukeboom, & Sparks, 2012). As previous research
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showed that small linguistic variations (i.e. negations or afﬁrmations) can impact the
health message (Burgers et al., 2012), it might be interesting to test whether these varia-
tions can change the effect of information on CPR.
We did not ﬁnd evidence for the activation of stereotypical cognition or patient cate-
gory associations after reading the experimental information. However, patients high in
stigma consciousness had overall more stereotypical associations about cognition such
as being ‘dumb’. In addition, these patients showed deactivated levels of the patient cat-
egory. As especially patients high in stigma consciousness were more prone to AIE,
these ﬁndings point to the possibility that stigma conscious patients do not want to be
regarded as a patient and, as a result, try hard to disprove stereotypical expectations.
Future studies should further examine this line of reasoning.
A limitation of the current study is that patients were recruited online and that,
although we collected information about diagnosis and treatment, checking this self-
reported information and obtaining more information about patients’ medical history
was impossible. Information about cancer stage or treatment regimen was not obtained.
Future studies should include this information and study AIE in a more controlled
setting. In addition, the inﬂuence of expectancies of cognitive side effects prior to treat-
ment and effects of the experimental texts on expectancy levels should be measured.
Nocebo and placebo research shows the importance of enhancing positive expectancies,
however, it has not been investigated often whether an intervention (in text) designed at
changing expectations could reduce AIE. Finally, future studies should use a text for
the control condition comparable in length to the other two experimental conditions.
Although the present study shows that informing patients about cognitive side
effects of chemotherapy may have negative effects for a subgroup of patients, informing
patients on treatment (side effects) also has several positive outcomes. For example,
patients with fulﬁlled information needs have in general less depression and anxiety
and report a better health-related quality of life (Husson, Mols, & Van de Poll-Franse,
2010). Moreover, because of informed consent procedures, health practitioners are
required to inform patients about medical procedures and side effects of treatment and
medication. So the main question is not if treatment information needs to be communi-
cated to patients, but how to inform each individual patient about treatment side effects.
Although we found no positive effects of our intervention, we did demonstrate that
information can have a differential impact on experienced side effects as a function of
patient characteristics, which points to the importance of ‘patient-centered information
provision’ (Husson et al., 2010, p. 11). Wells and Kaptchuk (2012) suggest a ‘contextu-
alized informed consent procedure’, which takes into account ‘possible side effects, the
patient being treated and the particular diagnosis involved’, in order to prevent ‘the
increase of side effects through expectancy mechanisms due to informing patients about
side effects of medication’ (p. 1). Future research should further examine information-
based interventions to prevent these AIE in communicating about side effects in general
and about cognitive side effects of cancer treatment in particular. Effective psychologi-
cal and pharmacological interventions to diminish cognitive problems in cancer patients
are still scarce. Although several interventions seem promising, such as cognitive reha-
bilitation or physical activity interventions (see for a review Chan, McCarthy, Devenish,
Sullivan, & Chan, 2015), the current approach might be an addition to these other
approaches and could, for example, be integrated in psycho-educational material or
cognitive rehabilitation programmes.
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Finally, it is important to track changes in CPR and to examine possible contribut-
ing psychological factors before, during and after treatment, as research shows that pre-
treatment worry may contribute to CPR during treatment (Berman et al., 2014). Also,
women newly diagnosed with BC might react differently to information about side
effects than women several years after treatment. Future studies should examine CPR
and the duration of the information effects in a prospective design, to create a more nat-
uralistic situation and to determine the severity of the effect of the patient information.
Conclusion
This study made a ﬁrst attempt to identify risk factors for AIE regarding chemotherapy-
associated cognitive problems. Information about the cognitive side effects of
chemotherapy increased the frequency of CPR for BC patients high in stigma con-
sciousness. Informing women with BC about long-term (cognitive) side effects of treat-
ment without creating these side effects becomes increasingly important as BC survival
rates increase and more women return to work after BC treatment. Over the past years,
cognitive changes after cancer treatment have gained attention in research (Wefel, Kes-
ler, Noll, & Schagen, 2015), which may also have raised patients’ awareness of the
association between cognition and cancer treatment. In the future, it may be increas-
ingly important to develop effective interventions in the clinical setting in order to ﬁnd
a way to inform patients about cognitive side effects without worsening them.
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